https://www.selleckchem.com/products/mrtx1133.html
Of 405 MT patients treated with additional IA fibrinolytics, 209 (51.6%) received prior intravenous tPA. We did not observe an increased risk of sICH after administration of IA fibrinolytics as adjunct to MT (OR 1.06, 95% CI 0.64 to 1.76), nor excess mortality (0.81, 95% CI 0.60 to 1.08). Although the mode of reporting was heterogeneous, some studies observed improved reperfusion after IA fibrinolytics. The quality of evidence regarding peri-interventional administration of IA fibrinolytics in MT is low and limited to observational dat
Like
Comment
Share
